PROMOTING NEUROPROTECTION

BIONURE IN BRIEF

A clinical stage company developing first-in-class neuroprotectant drugs

Bionure is a clinical stage biotechnology company, an academic spin-off from IDIBAPS – Hospital Clinic of the University of Barcelona and the Spanish National Council CSIC (Spain). The company was founded in 2009 and has its headquarters in Barcelona, Spain.

 

Based on more than 15-year of research in neuroprotection, the company develops new first-in-class disease-modifier drugs able to slow down, stop or reverse the damaging process affecting neurons for the treatment of degenerative, ischemic, toxic and inflammatory diseases of the nervous system.

 

Since there are very high unmet needs associated to these diseases, Bionure aims at becoming a therapeutic game changer and bringing significant benefit to thousands to millions of patients enduring serious disabilities.

 

Bionure’s lead program demonstrated neuroprotective activity in several preclinical models and has successfully completed a clinical phase 1 study in the UK. In 2020, the company plans to start a phase 2 proof-of-concept trial in optic neuritis (orphan drug designation) and multiple sclerosis, to prove the efficacy of the compound in patients affected by neuronal damage.

 

Bionure has built a seasoned team of pharma R&D and corporate development professionals and an efficient ecosystem of vendors, CROs and advisors, including prominent scientific and clinical experts in the field of neurodegeneration, to further support the development of its programs.

 

The company is privately-held.  Initially supported by business angels, family offices and public grants, the company started to diversify its investor base with a first institutional VC, Alta Life Sciences, which led in 2018 the Series A financing round to support the Phase 1 program of BN201 and will help anchoring syndication of investors at futures rounds.

 

Our team

Top-tier professionals and experts working towards a common goal

laurent-nguyen
Dr. Laurent Nguyen
CEO
mar-masso
Mar Massó
COO
lucia-septien
Dr. Lucía Septién-Vélez
CMO
pablo-villoslada
Dr. Pablo Villoslada
Co-founder and CSO
joaquim-trias
Joaquim Trias
PhD; President at JPTS; Co-founder of Vicuron, Peninsula, Anthera, Tetraphase and Microcide
larry-steinman
Larry Steinman
MD; Professor of Neurology at Stanford University; Co-founder of Atreca, Nuon Therapeutics, Neurocrine Biosciences and Bayhill Therapeutics
stephen-hauser
Stephen Hauser
MD; Chairman and Professor of Neurology at UCSF
amir-bar-or
Amir Bar-Or
MD; Director of the Center for Neuroinflammation and Neurotherapies: Chief of the Multiple Sclerosis Center at the University of Pennsylvania Perelman School of Medicine (Philadelphia, USA)
ari-green
Ari Green
MD; Clinical Director of the UCSF MS Center; Director of the UCSF Neurodiagnostics Center
craig-smith
Craig Smith
MD; Advisor of the Bill and Melinda Gates Foundation
guy nohra
Guy P. Nohra
Partner at Alta Life Sciences (Chair)
montserrat-vendrell
Montserrat Vendrell
Partner at Alta Life Sciences (Vice Chair)
laurent-nguyen
Dr. Laurent Nguyen
CEO Bionure
salut-monras
Salut Monràs
CEO Valrà Finances
paul-frohna
Paul Frohna
Chief Medical Officer at Bioniz Therapeutics, Inc.
rajiv-mahadevan
Rahiv Mahadevan
Managing Director at Precision for Medicine

Partnerships

We look forward to pursuing partnership opportunities with industry leaders.

ms_cuadrado

The National MS Society mobilizes people and resources to drive research for a cure and to address the challenges of everyone affected by MS. The National MS Society is committed to achieving a world free of MS. Bionure has been funded by the National MS Society through Fast Forward program.

fastforward-cuadrado

Fast Forward, LLC is a nonprofit organization established by the National Multiple Sclerosis Society in order to accelerate the development of treatments for MS.

jofre_cuadrado

Reig Jofre is a pharmaceutical company focused on the research, development, manufacture and marketing of medicines and nutritional supplements, as well as on specialized manufacturing for third parties. Bionure collaborates with Reig Jofre in the formulation of its lead candidate.

gaem-cuadrado

Fundació GAEM is a non-profit organization supporting innovation to bring new therapeutics for multiple sclerosis patients.

myelin_cuadrado

The Myelin Repair Foundation (MRF) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis. Under the partnership with the MRF, Bionure’s BN201 has been shown to promote myelin repair.

Bionure has participated in the following projects. These projects have received funding from the Ministry of Science and Innovation, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011. They have been co-financed by the European Regional Development Fund (ERDF).

ministerio-b
unioneuropea-b

Bionure has received non-dilutive funding support from the following local, national and european governments:

accio-b
cdti-b
icex-b
european-comission-b
seventh-b

Nuevas aproximaciones terapéuticas para la Esclerosis Múltiple y la Esclerosis Lateral Amiotrófica: efectos modificadores de la enfermedad y neuroprotección

(expediente IPT-010000-2010-035) liderado por Advanced in Vitro Cell Technologies SA y en el que también participan Neurotec Pharma SL y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.

STOP-ELA: Aproximación multi-tecnológica para el desarrollo de nuevas terapias y sistemas avanzados de administración farmacológica para la Esclerosis Lateral Amiotrófica

(expediente IPT-2011-1091-900000) liderado por Neurotec Pharma SL y en el que también participan Advanced in Vitro Cell Technologies SA, Palo Biofarma SL, Natac Biotech SL, Universidad de Zaragoza y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer

Desarrollo de terapias neuroprotectoras para Esclerosis Múltiple

(expediente IPT-2011-1312-900000) liderado por Digna Biotech SL, y en que también participan la Fundación Privada Institut d’Investigació Biomèdica de Bellvitge y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.